We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bausch Health Companies Inc | NYSE:BHC | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.005 | -0.07% | 7.025 | 7.06 | 6.97 | 7.03 | 1,033,375 | 16:33:52 |
From May 2023 to May 2024
By Ben Glickman
Bausch Health Cos. has received approval from the Food and Drug Administration for Cabtreo, its topical gel for acne.
The Laval, Quebec-based pharmaceutical company said the treatment, which combines clindamycin phosphate, adapalene and benzoyl peroxide, is expected to become available in the first quarter of 2024.
The approved new drug application allows for the use of Cabtreo in treating acne vulgaris in patients 12 years and older.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
October 20, 2023 17:50 ET (21:50 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Bausch Health Companies Chart |
1 Month Bausch Health Companies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
